Call for Abstract
22nd International Congress on Prevention of Diabetes and Complications, will be organized around the theme “Diabetes from Monitoring to Management”
Diabetes Meeting 2017 is comprised of keynote and speakers sessions on latest cutting edge research designed to offer comprehensive global discussions that address current issues in Diabetes Meeting 2017
Submit your abstract to any of the mentioned tracks.
Register now for the conference by choosing an appropriate package suitable to you.
- Track 1-1Beta cell and Aging
- Track 1-2Role of non-beta cells in glucose homeostasis
- Track 1-3Role of DNA methylation in insulin secretion
- Track 1-4Genetic defects in insulin action
- Track 1-5Diabetes in specific ethnic groups
- Track 1-6Recent advances in Diabetic drugs
Reversing diabetes is a term used to describe interventions that reduce dependency on type 2 diabetes medications, effectively reversing the progression of the illness. With time and dedication, type 2 diabetes can be reversed and the results can be very rewarding with less tiredness and better all round health. Loss of body weight can be particularly beneficial in helping to reverse the progression of diabetes. In some cases, people may find they are able to come off medication, although blood sugar levels should be checked regularly as reversing progression of diabetes is not a cure.
- Track 2-1Type 1 diabetes
- Track 2-2Type 2 diabetes
- Track 2-3Treatment of diabetes naturally
- Track 2-4Hormone Balance
- Track 2-5Nutrition
With rising numbers of diagnosed diabetics, pharmaceutical manufacturers have capitalized on the burgeoning market for diabetes therapies. Manufacturers' efforts to develop non-invasive methods of insulin delivery are set to revolutionize the insulin therapy market, while demand for oral medications is on the upswing due to a growing Type 2 diabetic population and introduction of technologically advanced therapies for battling complications associated to Type 2 Diabetes like the most prevalent Diabetes Cardiomyopathy. With human embryonic stem cells as a starting point, the scientists are for the first time able to produce, in the kind of massive quantities needed for cell transplantation and pharmaceutical purposes, human insulin-producing beta cells equivalent in most every way to normally functioning beta cells. This will certainly help people recover the prognosis of the fatal disease like diabetes.
- Track 3-1Clinical Trials and New biomarkers under development
- Track 3-2Biostator: closed loop system
- Track 3-3Development of artificial Beta cells and pancreas
- Track 3-4Continuous Glucose Monitoring
- Track 3-5New drug treatments and devices for diabetes
- Track 3-6Development of insulin pump
- Track 3-7Pharmacotherapy in treatment of diabetes
- Track 3-8Inflammatory markers and Type 2 diabetes
- Track 3-9Molecular Markers for both metabolic syndrome and Hypoglycemia Responses
- Track 3-10Development of Insulin Pens and Novel Insulin Delivery technique
The global diabetes treatment market is undergoing significant transition driven by the advent of new analytical technologies and developments in diabetes treatment. There has been a drastic increase in the incidents of diabetes worldwide, owing to the rising level of lifestyles and obesity in global population. The diabetes treatment products include injectable diabetes drugs, oral drugs, insulin therapies, insulin pumps, insulin injection devices and blood glucose monitoring systems which eliminates the risk of reverse diabetes. According to the new report the world market for diabetes medications will reach $55.3bn in 2017. The anti-diabetic medicines industry generated $35.6bn in 2012, and its revenues will show strong growth to 2023. Monitoring glucose levels is critical for the management of diabetes and new and improved portable, less costly, easy-to-use, accurate and virtually painless blood glucose monitoring systems are now available to take control of the disease.
- Track 4-1Newer Diabetes Medications, TZDs, and Combinations
- Track 4-2What is a Better Second-Line Agent After Metformin: DPP-4 Inhibitors or SGLT-2 Inhibitors?
- Track 4-3MODY and its types
- Track 4-4Weighing the Benefits and Risks of Diabetes Drugs
- Track 4-5Genetics of Metabolic Syndrome
- Track 4-6Second- and Third-Line Pharmacotherapy for Type 2 Diabetes
- Track 4-7Endocrinopathies
Diabetes Mellitus is a dreadful disease and is found in all parts of the world, becoming a serious threat of mankind health. There are lots of chemical agents available to take control on the disease, but total recovery from diabetes is the question to the treatment. Alternative to these synthetic agents, natural cure by plants provides a potential source curing complications of hypoglycemia and reverse Diabetes are widely used in several traditional systems of medicine to prevent prediabetes. Other alternative therapies such as diabetic supplements, acupuncture, hydrotherapy, and yoga therapies are reported to have less likely side effects of conventional approaches for diabetes.
- Track 5-1Diabetes: Type 1 and Type 2
- Track 5-2Glycemic load
- Track 5-3Glycemic index
- Track 5-4Neonatal Diabetes
- Track 5-5Monogenic Forms of Diabetes
- Track 5-6Paediatric diabetes
- Track 5-7Immune Intervention diabetes
- Track 5-8Prediabetes
- Track 5-9Diabetes in children
- Track 5-10Neuropathic
- Track 5-11Genetics of metabolic syndrome: Challenges and relation with Diabetes Mellitus
- Track 5-12Idiopathic
- Track 5-13Latent autoimmune diabetes of adults
- Track 5-14Autoimmune Diabetes Mellitus
- Track 5-15Gestational Hyperglycaemia and Diabetes
- Track 5-16Continuous Glucose MonitoringArtificial and bio-artificial pancreas
Diabetes has increasingly become a lifestyle-related disease as it afflicts young and old. As the number of patients grows across the globe, there has never been a stronger and more urgent need for novel therapeutic measures in clinical and preclinical evaluation, that arrest the growth of the disease. The diabetes market, consisting mainly of Type 1 and Type 2 diabetes, is large and growing significantly. The global market value for diabetes therapies and diagnostics has reached to $48.5 billion. The largest segment of the market, insulin products, is worth $20.8 billion in the recent times, including administration and diagnostic devices. Monitoring devices and other related equipment, the second-largest market is established with an investment of $13.5 billion in which was proposed for $11.3. The fastest-growing segment of oral diabetic complication of hypoglycemia drugs manufacturing funding is $14.13 in present scenario of diabetes market.
- Track 6-1Non-invasive diagnostic tool and imaging of Diabetes
- Track 6-2Clinical diagnosis and laboratory tests
- Track 6-3Prediabetes, anti-diabetes and metabolic syndrome
- Track 6-4Hypoglycemia Awareness
- Track 6-5Herbs, Supplements and Alternative Medicines
- Track 6-6Yoga and diabetes
- Track 6-7Nutrion Therapy
- Track 6-8Reverse Diabetes
- Track 6-9Carbohydrate counting
With the growing awareness and information regarding preventive measures for combating fatal disease like diabetes, consumers are opting for proper food along with medicines. One can improve the health in a big way by making small changes to the diet, while still enjoying the favourite foods and taking pleasure from the meals. A diabetes diet is simply a healthy eating plan that is high in nutrients, low in fat, and moderate in calories. Manufacturers are now keen towards Diabetes Nutrition on introducing new low calorie food products with sugar substitutes and less oil, in view of the increasing consumer interest toward healthy eating and help prevent diabetes and its concomitant risk factors.
- Track 7-1Frontiers in the Diabetic Nutrition
- Track 7-2Association between Alcohol Consumption and Glycemic Status
- Track 7-3Non-Pharmacological Interventions to Reduce the Risk of Diabetes in People with Impaired Glucose Regulation
- Track 7-4Management of Inpatient Hyperglycemia
- Track 7-5Diabetic Diets for Frail Elderly Long-Term Care Residents with Type II Diabetes Mellitus
- Track 7-6Diet for Diabetes in Pregnancy
- Track 7-7Impact of food & nutrition in diabetes management
- Track 7-8Advanced nutrition and dietetics in diabetes
Diabetes mellitus type 2, formerly noninsulin-dependent diabetes mellitus is a metabolic disorder that is characterized by hyperglycaemia (high blood sugar) in the context of insulin resistance and relative lack of insulin.In type 2 diabetes, the cells in your child's body don’t respond to the insulin, and glucose builds up in her bloodstream. This is called insulin resistance. This could lead to other conditions in the future, like heart disease, blindness, and kidney failure.
- Track 8-1Improving Blood Cholesterol
- Track 8-2Food to Improve Blood Cholesterol
- Track 8-3Dealing with Triglycerides
- Track 8-4Diet-Related Factors
- Track 8-5projection of prevalence and cost of diabetes in Canada
- Track 8-6Development of Non-invasive Diagnostic Device for Diabetes
The original description of the metabolic syndrome by Reaven, consisted of obesity, insulin resistance, hypertension, impaired glucose tolerance or diabetes, hyperinsulinemia and dyslipidemia characterized by elevated triglyceride, and low HDL concentrations. All of the features described above are risk factors for atherosclerosis, and thus, metabolic syndrome constituted a significant risk for coronary heart disease. The features of obesity/overweight and insulin resistance also provided a significant risk for developing type 2 diabetes. The risks for coronary heart disease and diabetes with metabolic syndrome are greater than those for simple obesity alone, and therefore, an understanding of the pathogenesis and through it, a rational approach to its therapy are of prime importance. As our understanding of the action of insulin evolves to comprehensively include the recent discoveries, we can better see that insulin resistance is the basis of most if not all of the features of this syndrome. The original conceptualization of this syndrome was on the basis of resistance to the metabolic actions of insulin. Thus, hyperinsulinemia, glucose intolerance, type 2 diabetes, hypertriglyceridemia, and low HDL concentrations could be accounted for by resistance to the actions of insulin on carbohydrate and lipid metabolism. Although the features described above would to some extent explain the atherogenesis, Reaven has maintained that hyperinsulinemia itself contributes to atherogenicity, and thus, insulin is atherogenic, leading to the coronary heart disease and cerebrovascular disease associated with this syndrome.
Obesity probably leads to hypertension through increased vascular tone created by a reduced bioavailability of NO because of increased oxidative stress, increased asymmetric dimethylarginine (ADMA) concentrations, increased sympathetic tone, and increased expression of angiotensinogen by adipose tissue leading to an activation of the renin-angiotensin system. The last of these factors requires further critical investigation.
- Track 9-1Energy balance and Obesity
- Track 9-2Genetics of metabolic syndrome: Challenges and relation with Diabetes Mellitus
- Track 9-3Beta cell regeneration & encapsulation research
- Track 9-4Genetic Defects of Beta Cell Function
- Track 9-5New insights into beta cell signaling pathways
- Track 9-6The Canadian Diabetes Risk Assessment Questionnaire (CANRISK)
Diabetes patients with depression symptoms were less likely to be at their glucose goal (43% vs 50%; P = .0176) but more likely to be at their blood pressure goal (57% vs 51%; P = .0435). The association between lipids and depression symptoms was related to a lower rate for low-density lipoprotein testing (56% vs 68%; P < .0001). Treatment with antidepressants resulted in a greater percentage achieving glucose and blood pressure goals but not lipid goals. Depression seems to have a variable impact on achieving these clinical goals, perhaps because the goals have differing measurement logistics and biological profiles. Further research is needed to learn whether better treatment of depressive symptoms leads to improvements in meeting diabetes clinical goals.
- Track 10-1Behavioral Programs for Diabetes Mellitus
- Track 10-2Depressive Symptoms in Patients with Type 2 Diabetes
- Track 10-3Tai chi practice in diabetes
- Track 10-4Recurrent Depressive Disorder and Diabetes
- Track 10-5Mobile & IT Technologies for patients
Diabetes case reports are in-depth inquiries of an individual, crowd, occasion or public. The data are assembled from a diversity of places by various methods. The case study technique encompasses spotting what happens to, or reconstructing ‘the case history’ of a single participant or group of individuals, i.e. the idiographic approach. Case studies permits an investigator to investigate a topic in far more detailed and minute way. The case study is not itself a research method, but investigators choose methods of data collection and analysis that will generate material suitable for case studies. Most of this evidence is likely to be qualitative but the psychologist might collect numerical data as well and present in various diabetes conference and scientific sessions
Type 1 diabetes
Type 2 diabetes
Latent autoimmune diabetes of adults (LADA)
Preclinical safety evaluation of stem cell-based therapies for diabetes
Diabetes in culturally Diverse Populations: From Biology to Culture
Tests for type 1 and type 2 diabetes and prediabetes : Glycated hemoglobin (A1C) test: This blood test indicates your average blood sugar level for the past two to three months. It measures the percentage of blood sugar attached to hemoglobin, the oxygen-carrying protein in red blood cells. The higher your blood sugar levels, the more hemoglobin you'll have with sugar attached. An A1C level of 6.5 percent or higher on two separate tests indicates that you have diabetes. An A1C between 5.7 and 6.4 percent indicates pre-diabetes. Below 5.7 is considered normal.
If the A1C test results aren't consistent, the test isn't available, or if you have certain conditions that can make the A1C test inaccurate — such as if you're pregnant or have an uncommon form of hemoglobin (known as a hemoglobin variant) — your doctor may use the following tests to diagnose diabetes:
Random blood sugar test: A blood sample will be taken at a random time. Regardless of when you last ate, a random blood sugar level of 200 milligrams per deciliter (mg/dL) — 11.1 millimoles per liter (mmol/L) — or higher suggests diabetes.
Fasting blood sugar test. A blood sample will be taken after an overnight fast. A fasting blood sugar level less than 100 mg/dL (5.6 mmol/L) is normal. A fasting blood sugar level from 100 to 125 mg/dL (5.6 to 6.9 mmol/L) is considered prediabetes. If it's 126 mg/dL (7 mmol/L) or higher on two separate tests, you have diabetes.
Oral glucose tolerance test: For this test, you fast overnight, and the fasting blood sugar level is measured. Then you drink a sugary liquid, and blood sugar levels are tested periodically for the next two hours. A blood sugar level less than 140 mg/dL (7.8 mmol/L) is normal. A reading of more than 200 mg/dL (11.1 mmol/L) after two hours indicates diabetes. A reading between 140 and 199 mg/dL (7.8 mmol/L and 11.0 mmol/L) indicates pre-diabetes.
Tests for gestational diabetes:
Initial glucose challenge test: This will be begin the glucose challenge test by drinking a syrupy glucose solution. One hour later, you'll have a blood test to measure your blood sugar level. A blood sugar level below 140 mg/dL (7.2 to 7.8 mmol/L) is usually considered normal on a glucose challenge test, although this may vary at specific clinics or labs. If your blood sugar level is higher than normal, it only means you have a higher risk of gestational diabetes. Your doctor will order a follow-up test to determine if you have gestational diabetes.
Follow-up glucose tolerance testing: For the follow-up test, you'll be asked to fast overnight and then have your fasting blood sugar level measured. Then you'll drink another sweet solution — this one containing a higher concentration of glucose — and your blood sugar level will be checked every hour for a period of three hours. If at least two of the blood sugar readings are higher than the normal values established for each of the three hours of the test, you'll be diagnosed with gestational diabetes.
- Track 12-1Tests for type 1 and type 2 diabetes and prediabetes
- Track 12-2Glycated hemoglobin (A1C) test
- Track 12-3Random blood sugar test
- Track 12-4Tests for gestational diabetes
- Track 12-5Initial glucose challenge test
- Track 12-6Follow-up glucose tolerance testing
- Track 12-7Diabetic macular edema
Diabetic retinopathy is caused by changes in the blood vessels of the retina. When these blood vessels are damaged, they may leak blood and grow fragile new vessels. When the nerve cells are damaged, vision is impaired. These changes can result in blurring of your vision, hemorrhage into your eye, or, if untreated, retinal detachment. Diabetic retinopathy is the most common diabetic eye disease and a leading cause of blindness. People with untreated diabetes are 25 times more at risk for blindness than the general population. The longer a person has had diabetes, the higher the risk of developing diabetic retinopathy. Fortunately, with regular, proper primary eye care and treatment when necessary, the incidence of severe vision loss has been greatly reduced.
- Track 13-1Corticosteroids
- Track 13-2Mild and moderate nonproliferative retinopathy
- Track 13-3Severe and proliferative nonproliferative retinopathy
- Track 13-4Visual acuity testing
- Track 13-5Tonometry
- Track 13-6Pupil dilation
- Track 13-7Optical coherence tomography
- Track 13-8Anti-VEGF Injection Therapy
- Track 13-9Focal/grid macular laser surgery
- Track 13-10Vitrectomy
Diabetes throws a light in a growing epidemic imposing thoughtful social economic crisis around the nation. Despite scientific innovations and better healthcare research amenities the disease continues to burden numerous segments, especially middle and low income countries. The current trends designate the rise in premature death, posing a major threat to global development. The advancement in science and technology have observed the expansion of newer generation of nanomedicine in drugs discovery. Then, the documentation and clinical investigation of bioactive ingredients from plants have transformed the investigation on drug discovery and lead identification for diabetes management control.
- Track 14-1Drug Development Opportunities in Diabetes
- Track 14-2Methods to control or prevent diabetes in obese people
- Track 14-3Diabetes and parkinson
- Track 14-4Diabetic dyslipidemia
- Track 14-5Bioinformatics tools and techniques used in diabetes Research
- Track 14-6Epidemology and pathogenesis of diabetes
Diabetes Education: It includes diabetes education modules. The Diabetes Education Modules (2011) contain more than 800 slides and detailed speaker notes to reflect the objectives contained in the International Curriculum for Health Professionals Education. Health professionals anywhere in the world can adopt this resource to develop diabetes education programmes for other health professionals.
The consistent, evidence-based research and information provided in these materials are designed to help educators gain recognition for their training and assure governments and education organisations that the education programmes they offer are of a high standard.
Risk Factors: The risk factors for type 1 diabetes are still being researched. However, having a family member with type 1 diabetes slightly increases the risk of developing the disease. Environmental factors and exposure to some viral infections have also been linked to the risk of developing type 1 diabetes. Several risk factors have been associated with type 2 diabetes and include:
- Family history of diabetes
- Unhealthy diet
- Physical inactivity
- Increasing age
- High blood pressure
- Impaired glucose tolerance (IGT)
- History of gestational diabetes
- Poor nutrition during pregnancy
- Track 15-1Self-Management Education
- Track 15-2Diabetes and Lifestyle Intervention
- Track 15-3Pharmacotherapy
- Track 15-4Diabetes Management Education
- Track 15-5Impaired glucose tolerance (IGT) (Risk Factor)